Health
Amplia Therapeutics says ‘priming’ a tumour could improve outcomes for patients with pancreatic cancer – Small Caps
New research describing the fundamental biology behind Amplia Therapeutics’ (ASX: ATX) planned phase 2 clinical trial on pancreatic…
New research describing the fundamental biology behind Amplia Therapeutics (ASX: ATX) planned phase 2 clinical trial on pancreatic cancer patients has highlighted the potential benefits of using a focal adhesion kinase (FAK) inhibitor prior to administering…
Continue Reading
-
General12 hours agoAustralian celebrity chef Peter Russell-Clarke dies aged 89
-
Noosa News21 hours agoRainbow Beach surfer’s untold 7/7 story
-
Noosa News11 hours agoWoman airlifted to Brisbane hospital after big cat mauling at south-east Queensland zoo near Toowoomba
-
Noosa News11 hours agoUnvaccinated horse dies from Hendra virus as Queensland records first case in three years